{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:32:54Z","timestamp":1770823974975,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA044181"],"award-info":[{"award-number":["R01DA044181"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA044181"],"award-info":[{"award-number":["R01DA044181"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA044181"],"award-info":[{"award-number":["R01DA044181"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA044181"],"award-info":[{"award-number":["R01DA044181"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA044181"],"award-info":[{"award-number":["R01DA044181"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA044181"],"award-info":[{"award-number":["R01DA044181"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Amidst a sustained drug poisoning crisis, there is growing recognition in Canada of the need to expand injectable opioid agonist treatment (iOAT). iOAT is an intensive treatment that involves the daily self-administration of hydromorphone or diacetylmorphine under healthcare provider supervision, typically accompanied by other health and social services. While this treatment has demonstrated effectiveness in reducing drug use-related risks, high threshold characteristics may also create barriers to engagement. This study examined patients\u2019 experiences of barriers and facilitators to iOAT with attention to how social and structural factors (e.g., housing vulnerability, poverty) shape program engagement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study draws on qualitative interviews and fieldwork observations with people accessing four iOAT programs in Vancouver\u2019s Downtown Eastside neighbourhood from May 2018 to November 2019. Data included baseline and follow-up interviews and approximately 50\u00a0h of observational fieldwork. Analysis leveraged a structural vulnerability lens to examine how social and structural factors shape people\u2019s engagement with iOAT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Participants highlighted how improved access to health and social services, compassionate and relational care, and flexible and individualized approaches to treatment delivery that addresses and accounts for the structural vulnerabilities facilitated engagement in treatment. However, dosing supervision, operational capacity and medication formulation were experienced as barriers to treatment. These barriers were magnified by structural vulnerabilities such as housing instability and mobility challenges.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Study findings highlight how people navigate the barriers and facilitators to iOAT engagement in light of the structural vulnerabilities they experience. Adaptations to and ongoing support for iOAT programs may help to facilitate engagement and should focus on equity-oriented and patient- centered treatment models that includes the integration of social supports, support for relational care and treatment planning that supports patient autonomy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12954-025-01262-4","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T18:14:59Z","timestamp":1751652899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada"],"prefix":"10.1186","volume":"22","author":[{"given":"Samara","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"1262_CR1","unstructured":"Government of Canada SC. The Daily\u2014Changes in life expectancy by selected causes of death, 2017. 2019. https:\/\/www150.statcan.gc.ca\/n1\/daily-quotidien\/190530\/dq190530d-eng.htm"},{"issue":"4","key":"1262_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350.","journal-title":"Curr Opin Psychiatry"},{"key":"1262_CR3","unstructured":"Government of Canada. Federal actions on the overdose crisis. 2024. https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/federal-actions\/overview.html"},{"issue":"3","key":"1262_CR4","doi-asserted-by":"publisher","first-page":"e0000769","DOI":"10.1371\/journal.pgph.0000769","volume":"3","author":"MR D\u2019Orsogna","year":"2023","unstructured":"D\u2019Orsogna MR, B\u00f6ttcher L, Chou T. Fentanyl-driven acceleration of racial, gender and geographical disparities in drug overdose deaths in the United States. PLOS Global Public Health. 2023;3(3):e0000769.","journal-title":"PLOS Global Public Health"},{"key":"1262_CR5","unstructured":"First Nations Health Authority. First nations and the toxic drug poisoning crisis in BC Jan-Dec 2023. 2023."},{"key":"1262_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-024-02667-5","author":"M Cano","year":"2024","unstructured":"Cano M, Zachmeyer M, Salinas LA, Ferguson KM. Racial\/ethnic inequality in homelessness and drug overdose deaths in US States. Soc Psychiatry Psychiatr Epidemiol. 2024. https:\/\/doi.org\/10.1007\/s00127-024-02667-5.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"1262_CR7","unstructured":"CADTH. Injectable opioid agonist treatment for patients with opioid dependence: a review of clinical and cost-effectiveness. 2020. p. 29. https:\/\/www.cda-amc.ca\/injectable-opioid-agonist-treatment-patients-opioid-dependence-review-clinical-and-cost"},{"key":"1262_CR8","doi-asserted-by":"crossref","unstructured":"Kilmer B, Taylor J, Caulkins JP, Mueller PA, Ober AJ, Pardo B, et al. Considering Heroin-Assisted Treatment and Supervised Drug Consumption Sites in the United States. RAND Corporation. 2018. https:\/\/www.rand.org\/pubs\/research_reports\/RR2693.html","DOI":"10.7249\/RR2693"},{"issue":"38","key":"1262_CR9","doi-asserted-by":"publisher","first-page":"E1049","DOI":"10.1503\/cmaj.190344","volume":"191","author":"N Fairbairn","year":"2019","unstructured":"Fairbairn N, Ross J, Trew M, Meador K, Turnbull J, MacDonald S, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019;191(38):E1049\u201356.","journal-title":"CMAJ"},{"issue":"1","key":"1262_CR10","first-page":"E115","volume":"9","author":"E Eydt","year":"2021","unstructured":"Eydt E, Glegg S, Sutherland C, Meador K, Trew M, Perreault M, et al. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. Can Med Assoc Open Access J. 2021;9(1):E115\u201324.","journal-title":"Can Med Assoc Open Access J"},{"key":"1262_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003410.pub4\/full","author":"M Ferri","year":"2011","unstructured":"Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2011. https:\/\/doi.org\/10.1002\/14651858.CD003410.pub4\/full.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1262_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2015","unstructured":"Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction\u2020. Br J Psychiatry. 2015;207(1):5\u201314.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"1262_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiat. 2016;73(5):447\u201355.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"1262_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12954-023-00808-8","volume":"20","author":"R Ellefsen","year":"2023","unstructured":"Ellefsen R, W\u00fcsthoff LEC, Arnevik EA. Patients\u2019 satisfaction with heroin-assisted treatment: a qualitative study. Harm Reduct J. 2023;20(1):73.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1262_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1940-0640-9-21","volume":"9","author":"E Oviedo-Joekes","year":"2014","unstructured":"Oviedo-Joekes E, Marchand K, Lock K, Chettiar J, Marsh DC, Brissette S, et al. A chance to stop and breathe: participants\u2019 experiences in the North American Opiate Medication Initiative clinical trial. Addict Sci Clin Pract. 2014;9(1):21.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"1262_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12954-023-00785-y","volume":"20","author":"F Riley","year":"2023","unstructured":"Riley F, Harris M, Poulter HL, Moore HJ, Ahmed D, Towl G, et al. \u2018This is hardcore\u2019: a qualitative study exploring service users\u2019 experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England. Harm Reduct J. 2023;20(1):66.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1262_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13011-020-0253-y","volume":"15","author":"K Marchand","year":"2020","unstructured":"Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"12","key":"1262_CR18","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/add.16620","volume":"119","author":"RK Metcalfe","year":"2024","unstructured":"Metcalfe RK, Dobischok S, Bansback N, MacDonald S, Byres D, Lajeunesse J, et al. Client preferences for the design and delivery of injectable opioid agonist treatment services: results from a best\u2013worst scaling task. Addiction. 2024;119(12):2139\u201350.","journal-title":"Addiction"},{"issue":"1","key":"1262_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/dar.12573","volume":"37","author":"E Oviedo-Joekes","year":"2018","unstructured":"Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Lock K, et al. Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence. Drug Alcohol Rev. 2018;37(1):137\u201346.","journal-title":"Drug Alcohol Rev"},{"key":"1262_CR20","doi-asserted-by":"publisher","first-page":"108512","DOI":"10.1016\/j.jsat.2021.108512","volume":"132","author":"K Marchand","year":"2022","unstructured":"Marchand K, Palis H, Guh D, Lock K, MacDonald S, Brissette S, et al. A multi-methods and longitudinal study of patients\u2019 perceptions in injectable opioid agonist treatment: implications for advancing patient-centered methodologies in substance use research. J Subst Abuse Treat. 2022;132:108512.","journal-title":"J Subst Abuse Treat"},{"key":"1262_CR21","unstructured":"City of Vancouver. Downtown Eastside Plan Three Year Summary of Implementation (2017\u20132019). 2020. https:\/\/vancouver.ca\/files\/cov\/dtes-plan-implementation-summary-2017-2019.pdf"},{"issue":"12","key":"1262_CR22","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1111\/add.14417","volume":"113","author":"J Boyd","year":"2018","unstructured":"Boyd J, Collins AB, Mayer S, Maher L, Kerr T, McNeil R. Gendered violence and overdose prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada. Addiction. 2018;113(12):2261\u201370.","journal-title":"Addiction"},{"key":"1262_CR23","volume-title":"More harm than good: drug policy in Canada","author":"S Boyd","year":"2016","unstructured":"Boyd S, Carter C, MacPherson D. More harm than good: drug policy in Canada. Halifax: Fernwood Publishing; 2016."},{"key":"1262_CR24","doi-asserted-by":"publisher","first-page":"104631","DOI":"10.1016\/j.drugpo.2024.104631","volume":"134","author":"J Lavalley","year":"2024","unstructured":"Lavalley J, Steinhauer L, Bundy D, Kerr T, McNeil R. \u201cThey talk about it like it\u2019s an overdose crisis when in fact it\u2019s basically genocide\u201d: the experiences of Indigenous peoples who use illicit drugs in Vancouver\u2019s Downtown Eastside neighbourhood. Int J Drug Policy. 2024;134:104631.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1262_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.drugpo.2012.03.006","volume":"23","author":"E Hyshka","year":"2012","unstructured":"Hyshka E, Strathdee S, Wood E, Kerr T. Needle exchange and the HIV epidemic in Vancouver: lessons learned from 15 years of research. Int J Drug Policy. 2012;23(4):261\u201370.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1262_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11524-020-00489-9","volume":"98","author":"A Ivsins","year":"2021","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. \u201cIt\u2019s helped me a lot, just like to stay alive\u201d: a qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in Vancouver, Canada. J Urban Health. 2021;98(1):59\u201369.","journal-title":"J Urban Health"},{"issue":"3","key":"1262_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/0091450919856635","volume":"46","author":"S Boyd","year":"2019","unstructured":"Boyd S, Norton A. Addiction and heroin-assisted treatment: legal discourse and drug reform. Contemp Drug Probl. 2019;46(3):265\u201381.","journal-title":"Contemp Drug Probl"},{"issue":"1","key":"1262_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1477-7517-10-6","volume":"10","author":"S Boyd","year":"2013","unstructured":"Boyd S, NAOMI Patients Association. Yet they failed to do so: recommendations based on the experiences of NAOMI research survivors and a call for action. Harm Reduct J. 2013;10(1):6.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1262_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12954-017-0152-3","volume":"14","author":"S Boyd","year":"2017","unstructured":"Boyd S, Murray D, MacPherson D, SNAP. Telling our stories: heroin-assisted treatment and SNAP activism in the Downtown Eastside of Vancouver. Harm Reduct J. 2017;14(1):27.","journal-title":"Harm Reduct J"},{"issue":"8","key":"1262_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777\u201386.","journal-title":"N Engl J Med"},{"key":"1262_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","volume":"74","author":"KC Priest","year":"2019","unstructured":"Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019;74:257\u201365.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1262_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/01459740.2011.576725","volume":"30","author":"J Quesada","year":"2011","unstructured":"Quesada J, Hart LK, Bourgois P. Structural vulnerability and health: Latino migrant laborers in the United States. Med Anthropol. 2011;30(4):339\u201362.","journal-title":"Med Anthropol"},{"issue":"3","key":"1262_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/ACM.0000000000001294","volume":"92","author":"P Bourgois","year":"2017","unstructured":"Bourgois P, Holmes SM, Sue K, Quesada J. Structural vulnerability: operationalizing the concept to address health disparities in clinical care. Acad Med. 2017;92(3):299\u2013307.","journal-title":"Acad Med"},{"key":"1262_CR34","first-page":"134","volume-title":"Interviewing in social science research: a relational approach","author":"LA Fujii","year":"2017","unstructured":"Fujii LA. Interviewing in social science research: a relational approach. New York: Routledge; 2017. p. 134."},{"key":"1262_CR35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4324\/9781315146027","volume-title":"Ethnography: principles in practice","author":"M Hammersley","year":"2019","unstructured":"Hammersley M, Atkinson P. Ethnography: principles in practice. 4th ed. London: Routledge; 2019. p. 292.","edition":"4"},{"key":"1262_CR36","unstructured":"SAGE Publications Ltd. The coding manual for qualitative researchers. 2024. https:\/\/uk.sagepub.com\/en-gb\/eur\/the-coding-manual-for-qualitative-researchers\/book273583"},{"issue":"348","key":"1262_CR37","doi-asserted-by":"publisher","first-page":"116708","DOI":"10.1016\/j.socscimed.2024.116708","volume":"1","author":"S Mayer","year":"2024","unstructured":"Mayer S, Jenkins E, Fairbairn N, Fowler A, McNeil R. \u201cI\u2019m just searching to get better\u201d: constructions of treatment citizenship on injectable opioid agonist treatment. Soc Sci Med. 2024;1(348):116708.","journal-title":"Soc Sci Med"},{"issue":"2","key":"1262_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/09687637.2023.2176287","volume":"31","author":"T Magel","year":"2024","unstructured":"Magel T, Matzinger E, Blawatt S, Harrison S, MacDonald S, Amara S, et al. How injectable opioid agonist treatment (iOAT) care could be improved? Service providers and stakeholders\u2019 perspectives. Drugs Educ Prevent Policy. 2024;31(2):200\u201311.","journal-title":"Drugs Educ Prevent Policy"},{"issue":"116","key":"1262_CR39","doi-asserted-by":"publisher","first-page":"104025","DOI":"10.1016\/j.drugpo.2023.104025","volume":"1","author":"HL Poulter","year":"2023","unstructured":"Poulter HL, Walker T, Ahmed D, Moore HJ, Riley F, Towl G, et al. More than just \u2018free heroin\u2019: caring whilst navigating constraint in the delivery of diamorphine assisted treatment. Int J Drug Policy. 2023;1(116):104025.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1262_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1472-6963-14-271","volume":"14","author":"MK Constand","year":"2014","unstructured":"Constand MK, MacDermid JC, Dal Bello-Haas V, Law M. Scoping review of patient-centered care approaches in healthcare. BMC Health Serv Res. 2014;14(1):271.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"1262_CR41","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0277-9536(00)00098-8","volume":"51","author":"N Mead","year":"2000","unstructured":"Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51(7):1087\u2013110.","journal-title":"Soc Sci Med"},{"issue":"4","key":"1262_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/1468-0009.12349","volume":"96","author":"M Ford-Gilboe","year":"2018","unstructured":"Ford-Gilboe M, Wathen CN, Varcoe C, Herbert C, Jackson BE, Lavoie JG, et al. How equity-oriented health care affects health: key mechanisms and implications for primary health care practice and policy. Milbank Q. 2018;96(4):635\u201371.","journal-title":"Milbank Q"},{"issue":"1","key":"1262_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13722-023-00428-4","volume":"18","author":"S Dobischok","year":"2023","unstructured":"Dobischok S, Carvajal JR, Turner K, Jaffe K, Lehal E, Blawatt S, et al. \u201cIt feels like I\u2019m coming to a friend\u2019s house\u201d: an interpretive descriptive study of an integrated care site offering iOAT (Dr. Peter Centre). Addict Sci Clin Pract. 2023;18(1):73.","journal-title":"Addict Sci Clin Pract"},{"key":"1262_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-021-00535-y","volume":"18","author":"D Frank","year":"2021","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. \u201cIt\u2019s like \u2018liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18:1\u201310.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1262_CR45","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jsat.2011.12.008","volume":"43","author":"L Richardson","year":"2012","unstructured":"Richardson L, Wood E, Montaner J, Kerr T. Addiction treatment-related employment barriers: the impact of methadone maintenance. J Subst Abuse Treat. 2012;43(3):276\u201384.","journal-title":"J Subst Abuse Treat"},{"issue":"16","key":"1262_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13011-021-00358-x","volume":"5","author":"E Oviedo-Joekes","year":"2021","unstructured":"Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Subst Abuse Treat Prev Policy. 2021;5(16):22.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"1262_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12913-023-09558-6","volume":"23","author":"E Oviedo-Joekes","year":"2023","unstructured":"Oviedo-Joekes E, Dobischok S, Carvajal J, MacDonald S, McDermid C, Klakowicz P, et al. Clients\u2019 experiences on North America\u2019s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study. BMC Health Serv Res. 2023;23(1):553.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"1262_CR48","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jama.2022.1271","volume":"327","author":"T Gomes","year":"2022","unstructured":"Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, et al. Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation. JAMA. 2022;327(9):846\u201355.","journal-title":"JAMA"},{"key":"1262_CR49","unstructured":"Government of British Columbia. Government provides update on pharmacy investigations, prescribed alternatives. 02192025. https:\/\/news.gov.bc.ca\/releases\/2025HLTH0008-000127"},{"issue":"1","key":"1262_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40429-025-00655-6","volume":"12","author":"E Osagie","year":"2025","unstructured":"Osagie E, Horton J, Lawrence D, Hermes G, Garcia-Vassallo G. Methadone for opioid use disorder in the fentanyl era: navigating challenges and evolving strategies\u2014a narrative review. Curr Addict Rep. 2025;12(1):1\u201314.","journal-title":"Curr Addict Rep"},{"issue":"131","key":"1262_CR51","doi-asserted-by":"publisher","first-page":"104547","DOI":"10.1016\/j.drugpo.2024.104547","volume":"1","author":"A Norton","year":"2024","unstructured":"Norton A, Ivsins A, Holliday E, Sutherland C, Kerr T, Kennedy MC. A qualitative evaluation of a fentanyl patch safer supply program in Vancouver, Canada. Int J Drug Policy. 2024;1(131):104547.","journal-title":"Int J Drug Policy"},{"issue":"117","key":"1262_CR52","doi-asserted-by":"publisher","first-page":"104054","DOI":"10.1016\/j.drugpo.2023.104054","volume":"1","author":"S Mayer","year":"2023","unstructured":"Mayer S, Boyd J, Fairbairn N, Chapman J, Brohman I, Jenkins E, et al. Women\u2019s experiences in injectable opioid agonist treatment programs in Vancouver, Canada. Int J Drug Policy. 2023;1(117):104054.","journal-title":"Int J Drug Policy"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01262-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01262-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01262-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T19:02:55Z","timestamp":1751655775000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01262-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01262-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of British Columbia and Providence Health Care Research Ethics Board (H17-00557) conducted according to the Canadian Tri-Council policy regarding ethical conduct for research involving humans (TCPS 2). Informed consent was provided in writing by all participants at the onset of their participation, with ongoing verbal consent provided continually throughout the research process. Anonymity of participants was strictly safeguarded in the analysis, reporting, and storage of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}